CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.37 per share, which would represent a year-over-year decline of 39.8%. Our most recent consensus estimate is calling for quarterly revenue of $8.39 million, down 88.02% from the year-ago period. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Z ...